Protein composition and application thereof in diagnosis field

By screening and combining antigenic proteins such as DDX53, MMRN2, MKNK1, FGF12, NME3, HYLS1, TIA1, SSBP4 and ENO2, it is used for early diagnosis of lung cancer, and the problem of insufficient diagnostic sensitivity and specificity in the prior art has been solved, and the problem of insufficient diagnostic sensitivity and specificity in the prior art has been achieved. Higher diagnostic accuracy.

CN118914559APending Publication Date: 2024-11-08NANJING VERISILICON BIOTECHNOLOGY CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410912508.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-11-15
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The sensitivity and specificity of early diagnosis methods for lung cancer based on lung cancer autoantibodies in the prior art need to be further improved, and whether the new antigen protein combination is clinically significant and whether it can improve the sensitivity and specificity of early diagnosis of lung cancer is an urgent need in the industry. The problem solved.

Method used

Antigenic proteins such as antigen proteins DDX53, MMRN2, MKNK1, FGF12, NME3, HYLS1, TIA1, SSBP4 and ENO2 were screened and combined to detect lung cancer autologous IgG antibodies in serum, thereby improving the sensitivity and specificity of early diagnosis of lung cancer.

Benefits of technology

The sensitivity of this composition is 58%, specificity of 100%, and through the combination of different antigen proteins, the average value of sensitivity and specificity reaches 79% to 88%, which significantly improves the accuracy of early diagnosis of lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118914559A_ABST
    Figure CN118914559A_ABST
Patent Text Reader

Abstract

The invention discloses a protein composition and application thereof in the field of diagnosis, and belongs to the technical field of biological medicine. The protein composition comprises newly screened antigen proteins DDX53 and MMRN2, and any one or a combination of more of antigen proteins MKNK1, FGF12, PIP4K2C, NME3, CTAG1A, HYLS1, TIA1, SSBP4 and ENO2, the combination is used for antibody detection and early diagnosis of lung cancer, the sensitivity is 68-84%, the specificity is 90-100%, and the sensitivity and the specificity of early diagnosis of lung cancer are improved.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The patent application of this invention is a divisional application with application number 202311526662.8. The application date of the original application is: 2023-11-15. The name of the invention is: protein composition and its application in the field of diagnosis. Technical Field

[0002] The present application belongs to the field of biomedical technology, and specifically relates to a protein composition and its application in the field of diagnosis. Background Art

[0003] Protein is the material basis of life, the basic organic matter that constitutes cells, and the main bearer of life activities. In the human body, there are tens of thousands of types of proteins. Proteins have many important biological functions, including structural functions, enzyme catalysis, hormone regulation, immune function, transportation and energy storage. In view of the various biological functions of proteins, proteins existing in nature or artificially synthesized can be used as biomarkers for early diagnosis of various diseases, and can be used as antibodies for the treatment of various diseases.

[0004] As early as the 1960s, Robert W. Baldwin had confirmed that the human immune system can produce autoantibodies in the early stages of cancer development. Since the production of autoantibodies is a humoral immune response of the immune system to tumor-associated antigens, the level of autoantibodies in serum is much higher than the conventional antigen level. In addition, due to the high specificity and sensitivity of the antigen-antibody reaction, autoantibodies are easier to detect accurately than other markers even in the presence of a large amount of albumin interference in the serum. In other words, tumor autoantibodies are easier to detect than the corresponding tumor antigens. Therefore, early diagnosis of lung cancer by detecting autoantibodies has a broader prospect.

[0005] Lung cancer is one of the malignant tumors with the highest morbidity and mortality in my country and around the world. The prognosis of lung cancer is closely related to its development stage. The five-year survival rate of localized lung cancer is 53%, while the five-year survival rate is only 4% when metastasis occurs. Therefore, early screening and early diagnosis of lung cancer have become the key to prolonging the survival of patients and saving their lives. Early detection and timely prevention and treatment of lung cancer can significantly improve the survival rate and quality of life of patients.

[0006] In related technologies, Chapman et al. used enzyme-linked immunosorbent assay to compare the use of 6 antigen proteins (p53, NY-ESO-1, CAGE, GBU4-5, Annexin I and SOX2) and 7 antigen proteins (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD and MAGE A4) to detect the levels of corresponding autoantibodies in the serum of lung cancer patients and healthy controls. The results showed that the sensitivity and specificity of the combined detection of 6 autoantibodies were 39% and 89%, respectively, while the sensitivity and specificity of the combined detection of 7 autoantibodies were 41% and 91%, respectively. For another example, the Chinese invention patent with publication number CN103869086A records a serum autoantibody detection kit, which includes antigen proteins selected from five or more of 14 antigen proteins, including p53, Annexin1, CAGE, NY-ESO-1, HuD, Cyclin D, PGP9.5, GBU4-5, MDM2, GAGE7, XAGE1b, SOX2, MAGE A1 and MAGE A4. However, it was found that the antibodies corresponding to GBU4-5, SOX2, HuD, Cyclin D, NY-ESO-1, Annexin1, MAGE A1 and XAGE1b were almost indistinguishable between normal Chinese and lung cancer patients, and were not suitable for use as biomarkers for early or auxiliary diagnosis in Chinese. Such a gap may be due to differences caused by different ethnic groups detected. The patent specifically discloses 12 combinations and their corresponding sensitivities and specificities, including a combination of 4 to 7 antigen proteins, with a sensitivity of 27.5% to 62.5% and a specificity of 74.5% to 92.7%. When four antigen proteins (p53, NY-ESO-1, P62, CAGE) were selected, the sensitivity was 27.5% and the specificity was 87.3%, so the technical solution of four antigen proteins was not adopted. For example, the invention patents with publication numbers WO2018187228A1, WO2020069637A1 and US20220003768A1 record the early research results of the applicant, including a combination of 3 to 5 of the eight antigen proteins ETHE1, p53, CTAG1A, C1QTNF1, TEX264, CLDN2, NSG1 and HRas, and further screened 28 antigen proteins and the above eight antigen proteins using IgA, and evaluated the combination of any 2 to 6 antigen proteins, disclosing the results of 200 combinations, of which 67 combinations had high discrimination ability, 67 were medium, and the rest were low.For another example, the Chinese invention patent with publication number CN116482365A records a protein composition for detecting serum antibodies and its application, including 11 antigenic proteins, namely XAGE1A, RBPJ, CEACAM5, NSG1, TP53, DDHYLS1, NUDT14, PGK1, KRT19, MAGEC2 and SULT2B1. Any two or more of them are combined. When the number of combined proteins is 2, the two proteins XAGE1A and CEACAM5 have the best effect (sensitivity is 45.45%, specificity is 100%, and average value is 72.73%); when the number of combined proteins is 3, the three proteins XAGE1A, CEACAM5 and RBPJ have the best effect (sensitivity is 59.10%, specificity is 94.74%, and average value is 76.91%); when all 11 proteins are selected, the sensitivity is 86.36%, the specificity is 84.21%, and the average value is 85.29%.

[0007] It can be seen that the selection of antigen proteins, including the type and quantity of antigen proteins, significantly affects the sensitivity and specificity of early diagnosis of lung cancer. Are there other more suitable antigen proteins? Does the new antigen protein combination have clinical significance? Can the new antigen protein combination improve the sensitivity and specificity of early diagnosis of lung cancer? With the increasing incidence of tumors in my country, the detection method of autoantibodies with high sensitivity, high throughput and scalable application has become an urgent problem that the industry needs to solve. Summary of the invention

[0008] 1. Problem to be solved

[0009] This application aims to address the problem that the sensitivity and specificity of the prior art early diagnosis method for lung cancer based on lung cancer autoantibodies need to be further improved. Based on previous research, lung cancer-related antigens are further screened, and the screened lung cancer-related antigens are combined and used to detect lung cancer antibodies, which are further used for the early diagnosis of lung cancer.

[0010] 2. Technical solution

[0011] In order to solve the above problems, the technical solutions adopted in this application are as follows:

[0012] The present application provides an application of a protein composition in the preparation of a product for early diagnosis of lung cancer. The product comprises a protein composition, which includes antigenic proteins DDX53 and MMRN2, and also includes any one or more of antigenic proteins MKNK1, FGF12, PIP4K2C, NME3, CTAG1A, HYLS1, TIA1, SSBP4 and ENO2. The diagnostic product utilizes the protein composition to detect lung cancer autologous IgG antibodies in serum, thereby being used for early diagnosis of lung cancer.

[0013] Furthermore, the above-mentioned protein composition includes the antigenic proteins DDX53 and MMRN2, and also includes any one of the antigenic proteins MKNK1, FGF12, PIP4K2C, NME3, CTAG1A, HYLS1, TIA1, SSBP4 and ENO2.

[0014] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2 and MKNK1.

[0015] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2 and FGF12.

[0016] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2 and PIP4K2C.

[0017] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2 and NME3.

[0018] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2 and CTAG1A.

[0019] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2 and HYLS1.

[0020] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2 and TIA1.

[0021] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2 and SSBP4.

[0022] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2 and ENO2.

[0023] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2 and MKNK1, and also includes any one or more of antigenic proteins FGF12, PIP4K2C, NME3, CTAG1A, HYLS1, TIA1, SSBP4 and ENO2.

[0024] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2 and MKNK1, and also includes any one of antigenic proteins FGF12, PIP4K2C, NME3, CTAG1A, HYLS1, TIA1, SSBP4 and ENO2.

[0025] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1 and FGF12.

[0026] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1 and CTAG1A.

[0027] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1 and HYLS1.

[0028] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1 and SSBP4.

[0029] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1 and TIA1.

[0030] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1 and PIP4K2C.

[0031] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1 and NME3.

[0032] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1 and ENO2.

[0033] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1 and FGF12, and also includes any one or more of antigenic proteins PIP4K2C, NME3, CTAG1A, HYLS1, TIA1, SSBP4 and ENO2.

[0034] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1 and FGF12, and also includes any one of antigenic proteins PIP4K2C, NME3, CTAG1A, HYLS1, TIA1, SSBP4 and ENO2.

[0035] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12 and HYLS1.

[0036] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12 and CTAG1A.

[0037] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12 and TIA1.

[0038] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12 and SSBP4.

[0039] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12 and NME3.

[0040] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12 and PIP4K2C.

[0041] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12 and ENO2.

[0042] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12 and HYLS1, and also includes any one or more of antigenic proteins PIP4K2C, NME3, CTAG1A, TIA1, SSBP4 and ENO2.

[0043] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12 and HYLS1, and also includes any one of antigenic proteins PIP4K2C, NME3, CTAG1A, TIA1, SSBP4 and ENO2.

[0044] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1 and CTAG1A.

[0045] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1 and SSBP4.

[0046] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1 and TIA1.

[0047] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1 and NME3.

[0048] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1 and PIP4K2C.

[0049] Furthermore, the above protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1 and ENO2.

[0050] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1 and CTAG1A, and also includes any one or more of antigenic proteins PIP4K2C, NME3, TIA1, SSBP4 and ENO2.

[0051] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1 and CTAG1A, and also includes any one of antigenic proteins PIP4K2C, NME3, TIA1, SSBP4 and ENO2.

[0052] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A and SSBP4.

[0053] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A and TIA1.

[0054] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A and NME3.

[0055] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A and PIP4K2C.

[0056] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A and ENO2.

[0057] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A and SSBP4, and also includes any one or more of antigenic proteins PIP4K2C, NME3, TIA1 and ENO2.

[0058] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A and SSBP4, and also includes any one of antigenic proteins PIP4K2C, NME3, TIA1 and ENO2.

[0059] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A, SSBP4 and TIA1.

[0060] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A, SSBP4 and NME3.

[0061] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A, SSBP4 and PIP4K2C.

[0062] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A, SSBP4 and ENO2.

[0063] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A, SSBP4 and TIA1, and also includes any one or more of antigenic proteins PIP4K2C, NME3 and ENO2.

[0064] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A, SSBP4 and TIA1, and also includes any one of the antigenic proteins PIP4K2C, NME3 and ENO2.

[0065] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A, SSBP4, TIA1 and NME3.

[0066] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A, SSBP4, TIA1 and PIP4K2C.

[0067] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A, SSBP4, TIA1 and ENO2.

[0068] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A, SSBP4, TIA1 and NME3, and also includes antigenic proteins PIP4K2C and / or ENO2.

[0069] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A, SSBP4, TIA1, NME3 and PIP4K2C.

[0070] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A, SSBP4, TIA1, NME3 and ENO2.

[0071] Furthermore, the above-mentioned protein composition includes antigenic proteins DDX53, MMRN2, MKNK1, FGF12, HYLS1, CTAG1A, SSBP4, TIA1, NME3, PIP4K2C and ENO2.

[0072] Furthermore, the above-mentioned antigen protein DDX53 includes a polypeptide having an amino acid sequence as shown in SEQ ID NO:1, or includes a polypeptide having at least 80% homology with the sequence SEQ ID NO:1 and having the same or substantially the same function, or a polypeptide having the same or substantially the same function formed by replacing, deleting or adding one or more amino acids in the amino acid sequence shown in SEQ ID NO:1 (SEQ ID NO:1).

[0073] Furthermore, the antigen protein MMRN2 is a polypeptide having an amino acid sequence as shown in SEQ ID NO: 2, or a polypeptide having at least 80% homology with the sequence SEQ ID NO: 2 and having the same or substantially the same function, or a polypeptide having the same or substantially the same function formed by replacing, deleting or adding one or more amino acids in the amino acid sequence shown in SEQ ID NO: 2,(SEQ ID NO:2)。,

[0074] Further, the antigen protein MKNK1 comprises a polypeptide having an amino acid sequence as shown in SEQ ID NO:3, or a polypeptide having at least 80% homology with the sequence SEQ ID NO:3 and having the same or substantially the same function, or a polypeptide having the same or substantially the same function formed by substituting, deleting or adding one or more amino acids in the amino acid sequence shown in SEQ ID NO:3, MVSSQKLEKPIEMGSSEPLPIADGDRRRKKKRRGRATDSLPGKFEDMYKLTSELLGEGAYAKVQGAVSLQNGKEYAVKIIEKQAGHSRSRVFREVETLYQCQGNKNILELIEFFEDDTRFYLVFEKLQGGSILAHIQKQKHFNEREASRVVRDVAAALDFLHTKDKVSLCHLGWSAMAPSGLTAAPTSLGSSDPPTSASQVAGTTGIAHRDLKPENILCESPEKVSPVKICDFDLGSGMKLNNSCTPITTPELTTPCGSAEYMAPEVVEVFTDQATFYDKRCD LWSLGVVLYIMLSGYPPFVGHCGADCGWDRGEVCRVCQNKLFESIQEGKYEFPDKDWAHISSEAKDLISKLLVRDAKQRLSAAQVLQHPWVQGQAPEKGLPTPQVLQRNSSTMDLTLFAAEAIALNRQLSQHEENELAEEPEALADGLCSMKLSPPCKSRLARRRALAQAGRGEDRSPTAL (SEQ ID NO: 3).

[0075] Further, the above-mentioned antigen protein FGF12 includes a polypeptide having an amino acid sequence as shown in SEQ ID NO:4, or includes a polypeptide having at least 80% homology with the sequence SEQ ID NO:4 and having the same or substantially the same function, or a polypeptide having the same or substantially the same function formed by replacing, deleting or adding one or more amino acids in the amino acid sequence shown in SEQ ID NO:4, MESKEPQLKGIVTRLFSQQGYFLQMHPDGTIDGTKDENSDYTLFNLIPVGLRVVAIQGVKASLYVAMNGE GYLYSSDVFTPECKFKESVFENYYVIYSSTLYRQQESGRAWFLGLNKEGQIMKGNRVKKTKPSSHFVPKPI EVCMYREQSLHEIGEKQGRSRKSSGTPTMNGGKVVNQDST (SEQ ID NO:4).

[0076] Further, the above-mentioned antigen protein PIP4K2C includes a polypeptide having an amino acid sequence as shown in SEQ ID NO:5, or includes a polypeptide having at least 80% homology with the sequence SEQ ID NO:5 and having the same or substantially the same function, or a polypeptide having the same or substantially the same function formed by replacing, deleting or adding one or more amino acids in the amino acid sequence shown in SEQ ID NO:5, MASSSVPPATVSAATAGPGPGFGFASKTKKKHFVQQKVKVFRAADPLVGVFLWGVAHSINELSQVPPPVMLLPDDFKASSKIKVNNHLFHRENLPSHFKFKEYCPQVFRNLRDRFGIDDQDYLVSLTRNPPSESEGSDGRFLISYDRTLVIKEVSSEDIADMHSNLSNYHQYIVKCHGNTLLPQFLGM YRVSVDNEDSYMLVMRNMFSHRLPVHRKYDLKGSLVSREASDKEKVKELPTLRDMDFLNKNQKVYIGEEEKKIFLEKLKRDVEFLVQLKIMDYSLLLGIHDIIRGSEPEEEAPVREDE SEVDGDCSLTGPPALVGSYGTSPEGIGGYIHSHRPLGPGEFESFIDVYAIRSAEGAPQKEVYFMGLIDILTQYDAKKKAAHAAKTVKHGAGAEISTVHPEQYAKRFLDFITNIFA(SEQ ID NO:5).

[0077] Further, the above-mentioned antigen protein NME3 is a polypeptide comprising an amino acid sequence as shown in SEQ ID NO:6, or a polypeptide having at least 80% homology with the sequence SEQ ID NO:6 and having the same or substantially the same function, or a polypeptide having the same or substantially the same function formed by replacing, deleting or adding one or more amino acids in the amino acid sequence shown in SEQ ID NO:6, MICLVLTIFANLFPAACTGAHERTFLAVKPDGVQRRLVGEIVRRFERKGFKLVALKLVQASEELLREHYAEL RERPFYGRLVKYMASGPVVAMVWQGLDVVRTSRALIGATNPADAPPGTIRGDFCIEVGKNLIHGSDSVES ARREIALWFRADELLCWEDSAGHWLYE (SEQ ID NO:6).

[0078] Further, the above-mentioned antigen protein CTAG1A includes a polypeptide having an amino acid sequence as shown in SEQ ID NO:7, or includes a polypeptide having at least 80% homology with the sequence SEQ ID NO:7 and having the same or substantially the same function, or a polypeptide having the same or substantially the same function formed by replacing, deleting or adding one or more amino acids in the amino acid sequence shown in SEQ ID NO:7, MQAEGRGTGGSTGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGAARASGPGGGAPRGPHGG AASGLNGCCRCGARGPESRLLEFYLAMPFATPMEAELARRSLAQDAPPLPVPGVLLKEFTVSGNILTIRLT AADHRQLQLSISSCLQQLSLLMWITQCFLPVFLAQPPSGQRR (SEQ ID NO:7).

[0079] Furthermore, the antigen protein HYLS1 comprises a polypeptide having an amino acid sequence as shown in SEQ ID NO: 8, or comprises a polypeptide having at least 80% homology with the sequence SEQ ID NO: 8 and having the same or substantially the same function, or comprises a polypeptide having SEQ ID The amino acid sequence shown in NO:8 is replaced, deleted or added with one or more amino acids to form a polypeptide with the same or substantially the same function, MDPEERMLAAATAFTHIRAGQGEGDVRREAQSIQYDPYSKASVAPGKRPALPVQLQYPHVESNVPSETVSEASQRLRKPVMKRKVLRRKPDGEVLVTDESIISESESGTENDQDLWDLRQRLMNVQFQEDKESSFDVSQKFNLPHEYQGISQDQLICSLQREGMGSPAYEQDLIVASRPKSFILPKLDQLSRNRGKTDRVARYFEYKRDWDSIRLPGEDHRKELRWGVREQMLCRAEPQSKPQHIYVPNNYLVPTEKKRSALRWGVRCDLANGVIPRKLPFPLSPS (SEQ ID NO:8).

[0080] Further, the above-mentioned antigen protein TIA1 is a polypeptide comprising an amino acid sequence as shown in SEQ ID NO:9, or a polypeptide having at least 80% homology with the sequence SEQ ID NO:9 and having the same or substantially the same function, or a polypeptide having the same or substantially the same function formed by replacing, deleting or adding one or more amino acids in the amino acid sequence shown in SEQ ID NO:9, MEDEMPKTLYVGNLSRDVTEALILQLFSQIGPCKNCKMIMDTAGNDPYCFVEFHEHRHAAAALAAMNGRKIMGKEVKVNWATTPSSQKKDTSSSTVVSTQRSQDHFHVFVGDLSPEITTEDIKAAFAPFGRISDARVVKDMATGKSKGYGFVSFFNKWDANAIQQMGGQWLGGRQIRTNWATRKPPAPKSTYECRCIGEEKEMWNFGEKYARF (SEQ ID NO:9).

[0081] Furthermore, the antigen protein SSBP4 comprises a polypeptide having an amino acid sequence as shown in SEQ ID NO: 10, or a polypeptide having at least 80% homology with the sequence SEQ ID NO: 10 and having the same or substantially the same function, or a polypeptide having SEQ ID The amino acid sequence shown in NO:10 is replaced, deleted or added with one or more amino acids to form a polypeptide with the same or substantially the same function, MYAKGGKGSAVPSDSQAREKLALYVYEYLLHIGAQKSAQTFLSEIRWEKNITLGEPPGFLHSWWCVFWDLYCAAPDRREACEHSGEAKAFQDYSAAAAPSPVMGSMAPGDTMAAGSMAAGFFQGPPGSQPSPHNPNAPMMGPHGQPFMSPRFPGGPRPTLRMPSQPPAGLPGSQPLLPGAMEPSPRAQGHPSMGGPMQRVTPPRGMASVGPQSYGGGMRPPPNSLAGPGLPAMNMGPGVRGPWASPSGNSIPYSSSSPGSYTGPPGGGGPPGTPIMPSPGDSTNSSENMYTIMNPIGQGAGRANFPLGPGPEGPMAAMSAMEPHHVNGSLGSGDMDGLPKSSPGAVAGLSNAPGTPRDDGEMAAAGTFLHPFPSESYSPGMTMSV (SEQ ID NO:10).

[0082] Further, the antigen protein ENO2 is a polypeptide comprising an amino acid sequence as shown in SEQ ID NO: 11, or a polypeptide having at least 80% homology with the sequence SEQ ID NO: 11 and having the same or substantially the same function, or a polypeptide having the same or substantially the same function formed by replacing, deleting or adding one or more amino acids in the amino acid sequence shown in SEQ ID NO: 11, MSIEKIWAREILDSRGNPTVEVDLYTAKGLFRAAVPSGASTGIYEALELRDGDKQRYLGKGVLKAVDHINSTIAPALISSGLSVVEQEKLDNLMLELDGTENKSKFGANAILGVSLAVCKAGAAERELPLYRHIAQLAGNSDLILPVPAFNVINGGSHAGNKLAMQEFMILPVGAESFRDAMRLGAEVYHTLKG VIKDKYGKDATNVGDEGGFAPNILENSEALELVKEAIDKAGYTEKIVIGMDVAASEFYRDGKYDLDFKSPTDPSRYITGDQLGALYQDFVRDYPVVSIEDPFDQDDWAAWSKFTANVGIQIV GDDLTVTNPKRIERAVEEKACNCLLLKVNQIGSVTEAIQACKLAQENGWGVMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKYNQLMRIEEELGDEARFAGHNFRNPSVL(SEQ ID NO:11).

[0083] Furthermore, the at least 80% homology mentioned above includes 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% homology.

[0084] Furthermore, the above antigen protein is expressed in yeast cells and obtained through purification.

[0085] The present application also provides a method for preparing the above antigen protein, which specifically comprises the following steps:

[0086] (1) Using Gateway high-throughput cloning technology, the full-length cDNA of the antigen protein was cloned into the yeast expression vector pEGH-A to construct a yeast expression plasmid for the GST fusion protein;

[0087] (2) Transforming the yeast expression plasmid into Escherichia coli cells, amplifying and purifying the plasmid; performing restriction digestion and DNA sequencing verification on the purified plasmid, and selecting the correct plasmid to transform into yeast cells;

[0088] (3) Pick the transformed yeast clones, inoculate them into SC-Ura / Glucose liquid medium, and culture them with shaking at 30°C for 20 to 24 hours; transfer them to SC-Ura / Raffinose liquid medium, and culture them with shaking at 30°C overnight; when the OD600 absorbance value is greater than 1.0 on the second day, add galactose to a final concentration of 2%, and continue to culture them with shaking overnight; collect the yeast cells by centrifugation, and wash them twice with sterile water;

[0089] (4) Add lysis buffer and nickel beads, shake to break the cells, and recover the supernatant by centrifugation; add Glutathione Sepharose 4B beads to the supernatant, mix well, and shake at 4°C for 1 hour; collect the beads by centrifugation, and wash them three times with wash solution I and wash solution II respectively; add elution buffer, shake briefly to resuspend the beads, and shake at 4°C for 1 hour; centrifuge and collect the supernatant to obtain the antigen protein.

[0090] Furthermore, in the above-mentioned method for preparing the antigen protein, the components of the lysate include: 50mM Tris, pH 7.5, 100mM NaCl, 1mM EGTA, 10% Glycerol, 0.1% TritonX-100, 0.1% beta-mercaptoethanol (BME), 1mM PMSF (200mM in isopropanol), 50μM LLnL (50mM in DMSO), 1μM MG-132 (50mMin DMSO), Roche Protease inhibitor tablets (without EDTA) 1in 50ml.

[0091] Furthermore, in the above-mentioned method for preparing the antigen protein, the components of the washing solution I include: 50mM Tris, pH 7.5, 500mM NaCl, 1mM EGTA, 10% Glycerol, 0.1% TritonX-100, 0.1% beta-mercaptoethanol (BME), and 1mM PMSF.

[0092] Furthermore, in the above method for preparing the antigen protein, the components of the washing solution II include: 50 mM HEPES pH 7.5, 100 mM NaCl, 1 mM EGTA, 10% Glycerol, 0.1% beta-mercaptoethanol (BME), and 1 mM PMSF.

[0093] Furthermore, in the above method for preparing the antigen protein, the eluent components include: 50 mM HEPES pH 8.0, 100 mM NaCl, 30% Glycerol, 40 mM Glutathione (Reduced form), and 0.03% TritonX-100.

[0094] The present application also provides a solid phase carrier, which is coated with any of the above-mentioned protein compositions.

[0095] The present application also provides the use of the above protein composition in the preparation of a kit for early diagnosis of lung cancer, wherein the kit comprises any of the above protein compositions and is used to detect lung cancer autologous IgG antibodies in the serum of a subject, thereby being used for early diagnosis of lung cancer.

[0096] The present application also provides a kit for early diagnosis of lung cancer, which comprises any of the above-mentioned protein compositions. The kit can use the protein composition to detect lung cancer autologous IgG antibodies in the serum of a subject, thereby being used for early diagnosis of lung cancer.

[0097] Furthermore, the signal detection methods used in the above-mentioned kit include visible light colorimetry, chemiluminescence, and fluorescence.

[0098] Furthermore, the above kit also includes a color developer, a serum dilution buffer, a washing solution and a stop solution.

[0099] The present application also provides the use of the above-mentioned kit for early diagnosis of lung cancer in the early diagnosis of lung cancer.

[0100] Furthermore, the above application includes the following steps:

[0101] S1: Obtain serum samples from subjects;

[0102] S2: Use the kit to detect the expression level of autoantibodies in the serum samples of the subjects;

[0103] S3: Compare the expression level of the autoantibodies in the detected serum sample with the preset value. If it is greater than the preset value, it is determined that the patient has lung cancer.

[0104] The present application also provides a device for early diagnosis of lung cancer, the device comprising:

[0105] A sample acquisition module, used to obtain a serum sample from a subject;

[0106] A sample detection module, including any of the above-mentioned kits for early diagnosis of lung cancer, used to detect the expression level of autoantibodies in a serum sample of a subject;

[0107] Data processing and result output module: compare the expression level of autoantibodies in the serum samples of the subjects detected by the sample detection module with the preset value. If it is greater than the preset value, the result of lung cancer is output; otherwise, the result of not having lung cancer is output.

[0108] 3. Beneficial effects

[0109] Compared with the prior art, the present application has the following beneficial effects:

[0110] The protein composition provided by the present application and its application in the field of diagnosis, wherein the antigen protein wherein the antigen protein DDX53, MMRN2, MKNK1, FGF12, NME3, HYLS1, TIA1, and ENO2 are all newly screened antigen proteins of the present application, wherein the combination of the two antigen proteins DDX53 and MMRN2 is used to detect antibodies and perform early diagnosis of lung cancer, and its sensitivity is 58%, and its specificity is 100%, and it can achieve similar or better effects with less antigen protein. With any one or more combinations of antigen proteins MKNK1, FGF12, PIP4K2C, NME3, CTAG1A, HYLS1, TIA1, SSBP4 and ENO2, its average value of sensitivity and specificity (Discriminative ability) is 79% to 88%, which improves the sensitivity and specificity of early diagnosis of lung cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0111] Figure 1 This is a representative scan image of the HuProt chip.

[0112] Figure 2 This is the reaction signal of the antigen protein DDX53 on the chip. The left side is the lung cancer sample, and the right side is the healthy sample.

[0113] Figure 3 This is the result of SDA-PAGE gel electrophoresis and Coomassie brilliant blue staining of the antigen protein CTAG1A.

[0114] Figure 4-6 It is the OD value distribution of each antigen protein in 100 subject samples. DETAILED DESCRIPTION

[0115] The present application is further described below in conjunction with specific embodiments.

[0116] It should be noted that the terms such as "upper", "lower", "left", "right", "middle", etc. cited in this specification are only for the convenience of description and are not used to limit the scope of implementation. Changes or adjustments to their relative relationships should be regarded as the scope of implementation of this application without substantially changing the technical content.

[0117] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this application belongs; the term "and / or" used herein includes any and all combinations of one or more of the associated listed items.

[0118] If the specific conditions are not specified in the examples, the experiments were carried out under conventional conditions or conditions recommended by the manufacturer. If the manufacturers of the reagents or instruments are not specified, they are all conventional products that can be purchased commercially.

[0119] As used herein, the term "about" is used to provide flexibility and imprecision associated with a given term, measurement or value. The degree of flexibility for a particular variable can be easily determined by one skilled in the art.

[0120] As used herein, the term "at least one of" is intended to be synonymous with "one or more of." For example, "at least one of A, B, and C" explicitly includes only A, only B, only C, and also includes their respective combinations.

[0121] Concentration, amount and other numerical data can be presented in range format herein.It should be understood that such range format is only used for convenience and simplicity, and should be flexibly interpreted as not only including the numerical value clearly described as range limit, but also including all single numerical values ​​or sub-ranges contained in the range, just as each numerical value and sub-range are clearly described.For example, the numerical range of about 1 to about 4.5 should be interpreted as not only including the limit value of 1 to about 4.5 clearly described, but also including single numerals (such as 2,3,4) and sub-ranges (such as 1 to 3,2 to 4, etc.).The same principle is applicable to the scope of only narrating a numerical value, such as "less than about 4.5", which should be interpreted as including all the above-mentioned values ​​and ranges.In addition, no matter how the breadth of the described range or feature is, this explanation should be applicable.

[0122] Example 1

[0123] This embodiment provides screening of lung cancer-associated antigens, which specifically includes the following steps:

[0124] 100 serum samples collected from 80 lung cancer patients and 20 healthy individuals were analyzed on the HuProt human proteome chip. The HuProt chip was provided by CDI Laboratories, Inc. Each HuProt v3.0 chip consists of 20,240 human full-length proteins, covering approximately 80% of the human proteome. There were no significant differences in age, gender, or smoking history between the lung cancer group and the healthy group.

[0125] The HuProt chip was first incubated in blocking buffer (PBS containing 0.1% (v / v) Tween 20 and 3% BSA) at room temperature for 1 hour, and then a 1:1,000 diluted serum sample was added and incubated at room temperature for 1 hour. Wash three times with 1×TBST with gentle shaking for 10 minutes each time. The chip was incubated with 3 ml of 1,000-fold diluted Alexa647-labeled goat anti-human IgG antibody (Jackson Immuno, USA) at room temperature in the dark for 1 hour. Subsequently, the HuProt chip was washed three times with 1×TBST and then rinsed three times with double distilled water. The HuProt chip was dried and scanned with a Genepix 4000B chip scanner (Molecular Devices, USA). The scanning results are shown as follows. Figure 1 As shown, the antibody signals on the chip were acquired using GenePix Pro 6.0 software.

[0126] To select candidate antigen proteins, the median of the foreground signal value (Fij) at a given protein spot on the HuProt chip was extracted for analysis. Since each protein has two replicate spots on the chip, the average value of Fij for each protein is taken as its signal intensity Fp. All Fp on 100 HuProt chips were quantile normalized, and then a t-test was performed to identify antigen proteins with significant differences between the lung cancer group and the healthy group. The selection criteria were that the p-value of the t-test was less than 0.05, and the average Fp of the lung cancer group was more than 1.5 times higher than that of the healthy group. Antigen proteins DDX53, MMRN2, MKNK1, FGF12, NME3, HYLS1, TIA1, and ENO2 were identified by this method, and their IDs on the chip are shown in Table 1. The reaction signal of the antigen protein DDX53 on the chip is shown in Table 1. Figure 2 As shown, the left side is lung cancer sample and the right side is healthy sample.

[0127] In addition, the inventors also summarized previous studies and selected antigen proteins PIP4K2C, SSBP4 and CTAG1A as lung cancer-related antigen proteins, among which the antigen proteins PIP4K2C, SSBP4, and CTAG1A were selected from the reaction results of 69 lung cancer samples and 30 control samples on the HuProt chip. The selection criteria were that the diagnostic specificity for lung cancer samples was greater than 89%, and the average value of sensitivity and specificity (Discriminative ability) was greater than 53% (see US20220003768A1 for details).

[0128] Table 1 Antigen protein ID on chip

[0129] Clone Id Antigenic protein JHU16271 DDX53 JHU16011 MMRN2 JHU00052 MKNK1 JHU00314 FGF12 JHU00059 NME3 JHU01186 HYLS1 JHU01234 TIA1 JHU00604 ENO2 JHU00151 PIP4K2C JHU06511 SSBP4 JHU17795 CTAG1A

[0130] Example 2

[0131] This example provides a method for preparing the lung cancer-associated antigen protein in Example 1, which specifically comprises the following steps:

[0132] (1) Using Gateway high-throughput cloning technology, the full-length cDNA of the antigen protein was cloned into the yeast expression vector pEGH-A to construct a yeast expression plasmid for the GST fusion protein;

[0133] (2) Transforming the yeast expression plasmid into Escherichia coli cells, amplifying and purifying the plasmid; performing restriction digestion and DNA sequencing verification on the purified plasmid, and selecting the correct plasmid to transform into yeast cells;

[0134] (3) Pick the transformed yeast clones, inoculate them into 5 ml SC-Ura / Glucose liquid medium, and culture them with shaking at 30°C for 20 to 24 hours; transfer 1 ml into 300 ml SC-Ura / Raffinose liquid medium, and culture them with shaking at 30°C overnight; when the OD600 absorbance value is greater than 1.0 on the second day, add galactose to a final concentration of 2%, and continue to culture them with shaking overnight; collect the yeast cells by centrifugation, and wash them twice with sterile water;

[0135] (4) Add lysis buffer and nickel beads, shake to break the cells, and then centrifuge to recover the supernatant; add Glutathione Sepharose 4B beads to the supernatant, mix well, and shake at 4°C for 1 hour; collect beads by centrifugation, and wash them three times with wash buffer I and wash buffer II; add elution buffer, briefly shake to resuspend the beads, and shake at 4°C for 1 hour; centrifuge, take the supernatant, divide it into 10 μl, and freeze the rest in a -80°C refrigerator; the components of the lysis buffer include: 50mM Tris, pH 7.5, 100mM NaCl, 1mM EGTA, 10% Glycerol, 0.1% TritonX-100, 0.1% beta-mercaptoethanol (BME), 1mMPMSF (200mM in isopropanol), 50μM LLnL (50mM in DMSO), 1μM MG-132 (50mM in DMSO), Roche Protease inhibitor tablets (without EDTA) 1in 50ml; washing solution I components include: 50mM Tris, pH 7.5, 500mM NaCl, 1mM EGTA, 10% Glycerol, 0.1% TritonX-100, 0.1% beta-mercaptoethanol (BME), 1mM PMSF; washing solution II components include: 50mM HEPES pH 7.5, 100mM NaCl, 1mM EGTA, 10% Glycerol, 0.1% beta-mercaptoethanol (BME), 1mM PMSF; elution solution components include: 50mM HEPES pH 8.0, 100mM NaCl, 30% Glycerol, 40mM Glutathione (Reduced form), 0.03% TritonX-100.

[0136] (5) Perform SDA-PAGE gel electrophoresis and Coomassie Brilliant Blue staining on 10 μL of the protein to detect the molecular weight, concentration and purity of the target protein.

[0137] Taking the antigen protein CTAG1A as an example, Figure 3 The results of SDA-PAGE gel electrophoresis and Coomassie brilliant blue staining (molecular weight ruler on the left) show that the molecular weight of the GST fusion protein is about 48 kD, the concentration is about 1 mg / ml, and the purity is about 95%. The remaining proteins in Example 1 were prepared using the same method.

[0138] Example 3

[0139] This example provides the application of the lung cancer-associated antigens screened in Example 1 in the detection of lung cancer autoantibodies, including the following steps:

[0140] S1: Obtain serum samples from subjects, which were from the Affiliated Cancer Hospital of Sun Yat-sen University, including 20 healthy samples (HC1-HC20) and 80 lung cancer patients (LC1-LC80);

[0141] S2: Use the indirect ELISA method to detect autoantibodies, including using ELISA plates to coat 0.1 μg of lung cancer-related antigens, adding 100-fold diluted serum samples of subjects after blocking, using HRP-labeled anti-human IgG as the secondary antibody, terminating the reaction after washing and color development, and immediately detecting with an enzyme-labeled instrument. Specifically include:

[0142] (1) Dilute the antigen to 1 μg / mL using ELISA coating solution and add 100 μL of the coating solution to the ELISA plate at 37°C for 1 h. The coating solution is 10 mM PBS (PH = 7.4);

[0143] (2) Cleaning: Fill the ELISA plate with Elisa cleaning solution, spin dry, and repeat 3 times. The cleaning solution includes: 10 mM PBS (PH = 7.4), 4% Tween-20;

[0144] (3) Blocking: Elisa blocking solution 200 μl / well, 4°C, overnight, wherein the blocking solution includes: 10 mM PBS (PH=7.4), 5% BSA, 4% Tween-20;

[0145] (4) Cleaning: Fill the ELISA plate with Elisa cleaning solution, spin dry, and repeat 5 times;

[0146] (5) Adding serum samples: two blank control wells are reserved on each plate as background, and the remaining 94 wells can detect 47 samples, with two replicate wells for each sample; 100 μL of 100-fold diluted serum sample is added to each well and incubated at 37° C. for 30 min, wherein the sample diluent includes: 10 mM PBS (PH=7.4), 5% BSA;

[0147] (6) Cleaning: Fill the ELISA plate with Elisa cleaning solution, spin dry, and repeat 5 times;

[0148] (7) Secondary antibody: dilute HRP-labeled anti-human IgG secondary antibody with Elisa blocking solution; add 100 μL to each well and incubate at 37°C for 30 min;

[0149] (8) Cleaning: Fill the ELISA plate with Elisa cleaning solution, spin dry, and repeat 5 times;

[0150] (9) Color development: Mix color development solution A and color development solution B in a ratio of 1:1 and use it immediately after preparation; add 100 μL to each well and incubate at 37°C for 5 min;

[0151] (10) Termination: 50 μl / well of stop solution. Read the result immediately using an ELISA reader.

[0152] Result analysis:

[0153] The OD values ​​of 100 samples of subjects are as follows Figure 4-6 As shown, HC represents normal human samples and LC represents patient samples. Figure 4 It can be seen that there are differences in the expression levels of lung cancer autoantibodies in normal human samples and patient samples detected by 11 antigen proteins.

[0154] The maximum value or the second highest value in the normal sample is taken as the CUT-OFF value. When the detected OD value is greater than the CUT-OFF value, the subject is judged to have lung cancer. The above antigen proteins are combined, and the sensitivity and specificity of different combinations are shown in Table 2.

[0155] Table 2

[0156]

[0157]

[0158]

[0159]

[0160]

[0161]

[0162]

[0163]

[0164]

[0165]

[0166]

[0167]

[0168]

[0169] In the present application, when four antigen proteins (DDX53, MMRN2, FGF12 and MKNK1) are selected, the sensitivity is 73%, which is higher than the sensitivity (72.7%) when eight proteins are selected in the Chinese invention patent with publication number CN116482365A. When the eight antigen proteins (DDX53, MMRN2, TIA1, HYLS1, FGF12, MKNK1, SSBP4 and CTAG1A) of the present application are selected, the sensitivity is 81%, which is an increase of 11.42%. It can be seen that the protein composition in the present application has higher sensitivity and specificity, which is conducive to improving the accuracy of early diagnosis of lung cancer.

Claims

1. Use of a protein composition in the preparation of a product for early diagnosis of lung cancer, characterized in that: The product comprises a protein composition, which includes antigenic proteins DDX53 and MMRN2, and any one or more of antigenic proteins MKNK1, FGF12, NME3, TIA1 and ENO2; the diagnostic product utilizes the protein composition to detect lung cancer autologous IgG antibodies in serum, thereby being used for early diagnosis of lung cancer.

2. The use according to claim 1, characterized in that: The protein composition also includes any one, two or three of the antigenic proteins PIP4K2C, CTAG1A, HYLS1 and SSBP4.

3. Use of a protein composition in the preparation of a kit for early diagnosis of lung cancer, characterized in that: The kit comprises the protein composition according to any one of claims 1 or 2, and the kit uses the protein composition to detect lung cancer autologous IgG antibodies in the serum of a subject, thereby being used for early diagnosis of lung cancer.

4. The use according to claim 3, characterized in that: The steps include: S1: Obtain serum samples from subjects; S2: Use the kit to detect the expression level of lung cancer auto-IgG antibodies in the serum samples of the subjects; S3: Compare the expression level of lung cancer autologous IgG antibodies in the tested serum sample with a preset value. If the expression level is greater than the preset value, it is determined that the patient has lung cancer.

5. A device for early diagnosis of lung cancer, characterized in that: The device comprises: A sample acquisition module, used to obtain a serum sample from a subject; A sample detection module, comprising the kit for early diagnosis of lung cancer as described in claim 3, used for detecting the expression level of lung cancer autologous IgG antibodies in a serum sample of a subject; Data processing and result output module: compare the expression level of lung cancer autologous IgG antibodies in the serum samples of the subjects detected by the sample detection module with the preset value. If it is greater than the preset value, the result of lung cancer is output; otherwise, the result of not having lung cancer is output.